Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VACC - Vaccitech plc - ADR


Close
5
0.510   10.200%

Share volume: 165,353
Last Updated: Mon 06 Nov 2023 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$4.49
0.51
11.36%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
18%
Profitability 15%
Dept financing 3%
Liquidity 75%
Performance 10%
Company vs Stock growth
vs
Performance
5 Days
23.35%
1 Month
13.67%
3 Months
97.80%
6 Months
95.22%
1 Year
69.43%
2 Year
-67.35%
Key data
Stock price
$5.00
P/E Ratio 
-3.15
DAY RANGE
N/A - N/A
EPS 
-$1.44
52 WEEK RANGE
$1.64 - $4.54
52 WEEK CHANGE
$0.69
MARKET CAP 
192.733 M
YIELD 
N/A
SHARES OUTSTANDING 
38.547 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/09/2023
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$85,181
AVERAGE 30 VOLUME 
$50,629
Company detail
CEO:
Region: US
Website: vaccitech.co.uk
Employees: 109
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit

Recent news